US pharmaceutical giant Pfizer Inc and its German partner BioNTech SE have announced positive results from their trial of a vaccine candidate adapted to the Omicron variant of the coronavirus. Pfizer and BioNTech announced positive data from the phase 2/3 trial evaluating the safety, tolerability, and immunogenicity of Omicron-adapted Covid-19 vaccine candidates against Omicron. The companies reported positive data from two trials-one as a monovalent and the other bivalent, a combination of the Pfizer-BioNTech Covid-19 vaccine and a vaccine candidate targeting the spike protein of the Omicron …